William J. Foley

William Foley is a Senior Associate in the New York Office and a member of the Securities Litigation, Investigations and Enforcement practice group.

• Engagements

  Mr. Foley's representative engagements include:

  • Pfizer Inc. and certain of its directors in federal securities class actions and shareholder derivative litigation relating to the marketing and sale of the pharmaceuticals.
  • The Special Committee of the Board of Directors of a leading satellite television provider in fraud and shareholder derivative actions related to an attempted asset purchase.
  • Credit Suisse Securities (USA) LLC in litigation involving breach of contract claims related the conveyance of an interest in a mezzanine loan.
  • A financial institution in connection with an investigation and lawsuit initiated by the Federal Energy Regulatory Commission related to alleged manipulation of commodity prices.
  • An investment management firm in CDO litigation involving allegations of breach of contract and gross negligence in connection with the management of the CDO’s underlying reference portfolio.
  • A military defense contractor in cases litigated in California state court involving significant contract disputes, misappropriation of trade secrets and related claims, including a lawsuit involving claims by former employees alleging breach of oral contract and unlawful termination.
  • Johnson & Johnson and numerous individual defendants in a federal securities class action pending in the District of New Jersey arising out of alleged product liability lawsuits.
  • Board of Directors of McKesson Corporation in a shareholder derivative suit pending in the Northern District of California regarding the Company’s prior settlement with government regulators over allegedly unlawful opioid distribution.
  • Akari Therapeutics PLC and related individual defendants in a federal securities class action in the Southern District of New York regarding Company statements about clinical trials.
  • A life sciences company in a securities class action arising out of the FDA’s rejection of application for marketing approval of a medical device.